Sanara MedTech stock: Price History and Returns
SMTISanara MedTech's share price rose by 20.6% a year over the last 10 years, 553.4% in total.
This shows what Sanara MedTech Inc. has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 20 Nov 2026
Share Price Since 2007
How Sanara MedTech Has Performed
The stock has not yet recovered its largest drawdown of 99.6% between June 2008 and December 2018 and trades 93.5% below the high today. Since the low in December 2018 the share price has risen more than tenfold. In its best year, 2019, the share price more than doubled at +436.7%, the weakest was 2012 at −90%. 2025 was a weak year at −29.7%, well below the 10-year average of +20.6% a year.
From 2023 to 2025 the stock fell three years in a row. More calendar years ended with a loss than with a gain, 10 of 18 since 2008. Since the start of the year the stock is up 39.9%.
How Sanara MedTech Compares
Over 10 years Sanara MedTech beat the S&P 500: with dividends +20.6% a year against +14.3% for the index, in US dollars. Over one year, Sanara MedTech did better than 95% of the 44 other stocks in the Medical (Instruments & Supplies) industry. Over five years the figure was 71%. The highest share price returns over five years in the Medical (Instruments & Supplies) industry came from Bonesupport Holding, Pulse Biosciences and Asahi Intecc.
| Period | Sanara MedTech | S&P 500 |
|---|---|---|
| 1 year | +71.4% | +11% |
| 5 years | +0.8% | +10.6% |
| 10 years | +20.6% | +14.3% |
Returns of Industry Peers
Among its industry peers, Safilo Group led over one year (+24.9%) and Embecta trailed furthest (−56.2%).
| Stock | 1 year | 5 years |
|---|---|---|
| Safilo Group | +24.9% | +39.9% |
| Dynavox Group | −14.6% | no data |
| AngioDynamics | −9.6% | −62.3% |
| Embecta | −56.2% | no data |
| COLTENE Holding | +3.6% | −54.7% |
What Became of $1,000
$1,000 invested in Sanara MedTech 10 years ago is worth $6,534 today.
With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 20 Nov 2026.
Returns by Period
| Period | Total | Per year |
|---|---|---|
| 1 year | +71.4% | +71.4% |
| 3 years | −1.3% | −0.4% |
| 5 years | +4.3% | +0.8% |
| 10 years | +553.4% | +20.6% |
| 15 years | +55.6% | +3% |
| Since 2007 | +553.4% | +9.9% |
Returns by Calendar Year
Figures as a table
| Year | Closing price | Return |
|---|---|---|
| 2026 to date | $32.67 | +39.9% |
| 2025 | $23.35 | −29.7% |
| 2024 | $33.20 | −19.2% |
| 2023 | $41.10 | −9.7% |
| 2022 | $45.50 | +54% |
| 2021 | $29.55 | −40.8% |
| 2020 | $49.90 | +209.9% |
| 2019 | $16.10 | +436.7% |
| 2018 | $3.00 | −50% |
| 2017 | $6.00 | +50% |
| 2016 | $4.00 | −55.6% |
| 2015 | $9.00 | +50% |
| 2014 | $6.00 | −45.5% |
| 2013 | $11.00 | +175% |
| 2012 | $4.00 | −90% |
| 2011 | $40.00 | 0% |
| 2010 | $40.00 | −81.8% |
| 2009 | $220.00 | −34.3% |
| 2008 | $335.00 | +231.7% |
Peak Price and Largest Drawdown
This is the pure share price return in US dollars from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
